Skip to content
Apto-Gen logo — Molecular solutions engineered to your application

Apto-Gen

Molecular solutions engineered to your application

Founded 2019 United Kingdom London, United Kingdom 7 employees Biotechnology, Health Care

General Information

Company Name Apto-Gen
Founded Year 2019
Location United Kingdom London, United Kingdom
Employees 7
Industries Biotechnology, Health Care
Social

BounceWatch is an independent company data service, not affiliated with Apto-Gen. To contact Apto-Gen, visit apto-gen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Apto-Gen compare?

A PDF of Apto-Gen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Apto-Gen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Apto-Gen

Apto-Gen is a biotechnology startup based in the United Kingdom, founded in 2019. Their slogan, "Molecular solutions engineered to your application," encapsulates their dedication to providing customized PCR and qPCR solutions for various applications. The company specializes in developing market-leading molecular biology reagents for integration into test devices and assays for human and animal diagnostics companies. Apto-Gen's key focus is on lyophilization-compatible enzyme and reagent technologies, aiming to provide more environmentally sustainable products by reducing cold chain storage and wastage. This strategic approach not only emphasizes their commitment to innovation but also showcases their dedication to eco-friendly solutions. The startup also prides itself on its customer-centric approach, identifying with its customers' quality systems, and meeting specific design requirements and project time frames to deliver bespoke and innovative products. With a firm foundation in the healthcare industry, Apto-Gen holds significant potential in a rapidly evolving market and could be an attractive investment opportunity for venture capital firms seeking to support innovative solutions in the biotechnology sector.

Business keywords: molecular biology, PCR, qPCR, diagnostics, enzyme technologies, reagent manufacturing, lyophilization, customized solutions, DNA detection, RNA detection, bespoke products, market-leading

No funding data available for Apto-Gen yet.

Apto-Gen Alternatives & Competitors

View All Alternatives
Apto-Gen vs

Delivering one-of-a-kind PCR solutions tailored to customer needs and contributing to a better world...

4 employees
Biotechnology, Health Care
Apto-Gen vs

Empirical Bioscience is now a part of Fortis Life Sciences.

Venture round
12 employees
Biotechnology, Health Care
Apto-Gen vs

Contact us via [email protected]

Private Equity
10 employees
Biotechnology, Health Care

FAQ About Apto-Gen

Molecular solutions engineered to your application
Apto-Gen was founded in 2019.
Apto-Gen is headquartered in London, United Kingdom.
Apto-Gen operates in Biotechnology and Health Care. Its work centres on molecular biology, PCR, qPCR and diagnostics.
Apto-Gen has approximately 7 employees.
Top alternatives and competitors to Apto-Gen include Advanced Molecular Diagnostics Ltd., Empirical Bioscience Inc. | Fortis Life Sciences, BioEcho Life Sciences, Fast MDx Ltd, Bioeksen R&D Technologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Apto-Gen and Advanced Molecular Diagnostics Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Apto-Gen, https://bouncewatch.com/company/apto-gen, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout